Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Rilzabrutinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Clirnet teams-up African Medical Associations to transform healthcare education
    Clirnet teams-up African Medical Associations to transform healthcare education

    29 Apr 2024

    // BUSINESSMICRO

    https://businessmicro.in/business/clirnet-teams-up-with-african-medical-associations-to-revolutionize-healthcare-education/

    BUSINESSMICRO
    29 Apr 2024
    Share Share
    Rilzabrutinib LUNA 3 Phase 3 Study Met Primary Endpoint in ITP
    Rilzabrutinib LUNA 3 Phase 3 Study Met Primary Endpoint in ITP

    23 Apr 2024

    // PRESS RELEASE

    https://www.sanofi.com/en/media-room/press-releases/2024/2024-04-23-05-00-00-2867327

    PRESS RELEASE
    23 Apr 2024
    Share Share
    Phase 2 results shows rilzabrutinib improved disease activity in urticaria
    Phase 2 results shows rilzabrutinib improved disease activity in urticaria

    24 Feb 2024

    // PRESS RELEASE

    https://www.sanofi.com/en/media-room/press-releases/2024/2024-03-11-06-00-00-2843456

    PRESS RELEASE
    24 Feb 2024
    Share Share
    This drug for blood disorder shows promise in phase 1-2 clinical trial
    This drug for blood disorder shows promise in phase 1-2 clinical trial

    18 Apr 2022

    // ET HEALTH

    https://health.economictimes.indiatimes.com/news/pharma/this-drug-for-blood-disorder-shows-promise-in-phase-1-2-clinical-trial/90912678

    ET HEALTH
    18 Apr 2022
    Share Share
    Positive Ph1/2 study results of rilzabrutinib peoplewith immune thrombocytopenia
    Positive Ph1/2 study results of rilzabrutinib peoplewith immune thrombocytopenia

    14 Apr 2022

    // PRESS RELEASE

    https://www.sanofi.com/en/media-room/press-releases/2022/2022-04-14-07-00-00-2422388

    PRESS RELEASE
    14 Apr 2022
    Share Share
    Positive Phase 1/2 study results of rilzabrutinib in immune thrombocytopenia
    Positive Phase 1/2 study results of rilzabrutinib in immune thrombocytopenia

    14 Apr 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/04/14/2422388/0/en/Press-Release-Positive-Phase-1-2-study-results-of-rilzabrutinib-in-people-with-immune-thrombocytopenia-published-in-The-New-England-Journal-of-Medicine.html

    GLOBENEWSWIRE
    14 Apr 2022
    Share Share